Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research10/27/2026Positive
DGX
Quest Diagnostics IncorporatedNYSEHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$28.21B
P/E Ratio
25.36
EPS
$10.08
Beta
0.55
52W High
$259.00
52W Low
$168.34
50-Day MA
$239.37
200-Day MA
$213.79
Dividend Yield
1.33%
Profit Margin
9.54%
Forward P/E
21.23
PEG Ratio
1.66
About Quest Diagnostics Incorporated
Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
Fundamentals
| Revenue (TTM) | $11.84B |
| Gross Profit (TTM) | $3.93B |
| EBITDA | $2.35B |
| Operating Margin | 15.60% |
| Return on Equity | 15.30% |
| Return on Assets | 6.61% |
| Revenue/Share (TTM) | $108.14 |
| Book Value | $69.38 |
| Price-to-Book | 3.68 |
| Price-to-Sales (TTM) | 2.38 |
| EV/Revenue | 2.838 |
| EV/EBITDA | 14.34 |
| Quarterly Earnings Growth (YoY) | 28.70% |
| Quarterly Revenue Growth (YoY) | 10.00% |
| Shares Outstanding | $110.37M |
| Float | $109.46M |
| % Insiders | 0.43% |
| % Institutions | 98.56% |
Historical Volatility
HV 10-Day
24.79%
HV 20-Day
22.11%
HV 30-Day
21.39%
HV 60-Day
22.16%
HV Rank
31.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($257.27 target)
2
Strong Buy7
Buy7
Hold1
Strong SellLatest News
Riverwater Partners Sustainable Value Strategy Q3 2026 Portfolio Update
The Sustainable Value Strategy trailed its benchmark, the Russell 2500 Value Index, in the third quarter. New positions include Lineage, Birkenstock, Matador Resources, KBR and ICON. InterDigital, Stevanato Group and Exelixis rounded out our top contributors.
Seeking Alpha10/27/2026Neutral
Quest Diagnostics Upgraded After Strong Q3, While Also Announcing New Test For Alzheimer's
Quest Diagnostics is upgraded to a strong buy, driven by robust earnings momentum, sector resilience, and sustained outperformance versus benchmarks. DGX delivered its fourth consecutive earnings beat, with Q3 revenue up 10% YoY and EPS up 28.7%, prompting raised full-year guidance. Quest's competitive edge is reinforced by superior margins, a strong ROE above 15%, ongoing innovation, and an investment-grade balance sheet with declining leverage.
Seeking Alpha10/27/2026Positive
Lab testing giant Quest Diagnostics confirms patients' personal and health data was compromised during breach
Medical lab testing giant Quest Diagnostics has confirmed a cyberattack and data breach affecting an as-yet unspecified amount of sensitive patient information stored in its systems, according to a legally required disclosure with U.S. regulators.
TechCrunch10/23/2026Negative
Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research10/23/2026Positive
DGX Q3 Earnings & Revenues Beat, '26 View Raised, Stock Down in Pre-Market
Quest Diagnostics beats Q3 earnings and revenue estimates, raises its 2026 outlook on strong testing demand and margin gains, yet shares dip in pre-market trading.
Zacks Investment Research10/22/2026Neutral
What Quest Diagnostics (DGX) Said on Its Q3 Earnings Call
Quest Diagnostics NYSE: DGX reported third-quarter 2026 revenue growth of 10% and adjusted earnings-per-share growth of more than 15%, citing demand across its physician, hospital and consumer channels as well as productivity gains from automation and artificial intelligence. The company raised and narrowed its full-year revenue and earnings outlook.
MarketBeat10/22/2026Positive
Quest Diagnostics: 3 Key Takeaways for Long-Term Investors
Quest Diagnostics expects consumer health revenue growth to exceed 30% in 2026. Organic requisition volume increased 14.4% in the third quarter of 2026.
The Motley Fool10/22/2026Neutral
Quest Diagnostics Incorporated (DGX) Q3 2026 Earnings Call Transcript
Quest Diagnostics Incorporated (DGX) Q3 2026 Earnings Call Transcript
Seeking Alpha10/22/2026Neutral
Quest Diagnostics (DGX) Q3 Earnings and Revenues Beat Estimates
Quest Diagnostics (DGX) came out with quarterly earnings of $3 per share, beating the Zacks Consensus Estimate of $2.85 per share. This compares to earnings of $2.6 per share a year ago.
Zacks Investment Research10/22/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DGX and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 11/7/2026